Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma

Cancer Immunology, Immunotherapy

Volumn 60, Issue 8, 2011, Pages 1075-1084

  Kobayashi, Hirohito ^a   Tanaka, Yoshimasa ^b   Yagi, Junji ^a   Minato, Nagahiro ^b   Tanabe, Kazunari ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

T cell; Cancer immunotherapy; Isopentenyl pyrophosphate; Nitrogen containing bisphosphonate; Pyrophosphomonoester; Renal cell carcinoma

Indexed keywords

RECOMBINANT INTERLEUKIN 2; ZOLEDRONIC ACID;

ADOPTIVE TRANSFER; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CD3+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; CYTOTOXICITY; DISEASE SEVERITY; EX VIVO STUDY; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; KIDNEY CARCINOMA; LUNG METASTASIS; LYMPHOCYTE FUNCTION; LYMPHOCYTE TRANSFER; MALE; NEPHRECTOMY; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SYMPTOM; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; CARCINOMA, RENAL CELL; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPHOSPHORUS COMPOUNDS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 79960903905     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1021-7     Document Type: Article

References (44)

1. AC Hayday 2009 γδ T cells and the lymphoid stress-surveillance response Immunity 31 184 196 19699170 10.1016/j.immuni.2009. 08.006 1:CAS:528:DC%2BD1MXhtFOgsL7N
2. Y Tanaka CT Morita E Nieves MB Brenner BR Bloom 1995 Natural and synthetic non-peptide antigens recognized by human γδ T cells Nature 375 155 158 7753173 10.1038/375155a0 1:CAS:528:DyaK2MXls1Wisrk%3D
3. Y Tanaka S Sano E Nieves G De Libero D Rosa RL Modlin MB Brenner BR Bloom CT Morita 1994 Nonpeptide ligands for human γδ T cells Proc Natl Acad Sci U S A 91 8175 8179 8058775 10.1073/pnas.91.17.8175 1:CAS:528: DyaK2cXlsFGitrY%3D (Pubitemid 24253909)
4. P Constant F Davodeau MA Peyrat Y Poquet G Puzo M Bonneville JJ Fournie 1994 Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands Science 264 267 270 8146660 10.1126/science.8146660 1:CAS:528: DyaK2cXis1OksLY%3D
5. Y Kato Y Tanaka F Miyagawa S Yamashita N Minato 2001 Targeting of tumor cells for human γδ T cells by nonpeptide antigens J Immunol 167 5092 5098 11673519 1:CAS:528:DC%2BD3MXotVWjs7w%3D (Pubitemid 33009743)
6. JF Bukowski CT Morita Y Tanaka BR Bloom MB Brenner H Band 1995 Vγ2 Vδ2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer J Immunol 154 998 1006 7529807 1:CAS:528:DyaK2MXjt1KktLo%3D
7. V Kunzmann E Bauer M Wilhelm 1999 γ/δ T-cell stimulation by pamidronate N Engl J Med 340 737 738 10068336 10.1056/NEJM199903043400914 1:STN:280:DyaK1M7ltVSrsQ%3D%3D (Pubitemid 29110764)
8. F Miyagawa Y Tanaka S Yamashita N Minato 2001 Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human γδ T cells by aminobisphosphonate antigen J Immunol 166 5508 5514 11313389 1:CAS:528:DC%2BD3MXjtFyrtbg%3D (Pubitemid 32374172)
9. HJ Gober M Kistowska L Angman P Jeno L Mori G De Libero 2003 Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells J Exp Med 197 163 168 12538656 10.1084/jem.20021500 1:CAS:528:DC%2BD3sXmt1Sjtg%3D%3D (Pubitemid 36152311)
10. M Jauhiainen H Monkkonen J Raikkonen J Monkkonen S Auriola 2009 Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures using liquid chromatography-electrospray ionization mass spectrometry J Chromatography B 877 2967 2975 10.1016/j.jchromb.2009.07.010 1:CAS:528:DC%2BD1MXhtFams7rP
11. M Bonneville E Scotet 2006 Human Vγ9 Vδ2 T cells: promising new leads for immunotherapy of infections and tumors Curr Opin Immunol 18 539 546 16870417 10.1016/j.coi.2006.07.002 1:CAS:528:DC%2BD28XpsVKqu7k%3D (Pubitemid 44311448)
12. D Kabelitz D Wesch W He 2007 Perspectives of γδ T cells in tumor immunology Cancer Res 67 5 8 17210676 10.1158/0008-5472.CAN-06-3069 1:CAS:528:DC%2BD2sXisFWhsg%3D%3D (Pubitemid 46142752)
13. D Kabelitz D Wesch E Pitters M Zoller 2004 Potential of human γδ T lymphocytes for immunotherapy of cancer Int J Cancer 112 727 732 15386388 10.1002/ijc.20445 1:CAS:528:DC%2BD2cXpslKru78%3D (Pubitemid 39435255)
14. GJ Morgan FE Davies WM Gregory K Cocks SE Bell AJ Szubert N Navarro-Coy MT Drayson RG Owen S Feyler AJ Ashcroft F Ross J Byrne H Roddie C Rudin G Cook GH Jackson JA Child On behalf of the National Cancer Research Institute Haematological Oncology Clinical Study Group 2010 First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial Lancet 376 1989 1999 21131037 10.1016/S0140-6736(10)62051-X 1:CAS:528:DC%2BC3cXhsFCqsLnL
15. H Kobayashi Y Tanaka J Yagi H Toma T Uchiyama 2001 γ/δ T cells provide innate immunity against renal cell carcinoma Cancer Immunol Immunother 50 115 124 11419178 10.1007/s002620100173 1:CAS:528: DC%2BD3MXltFWjtbk%3D (Pubitemid 32480555)
16. Kobayashi H, Tanaka Y, Nakazawa H, Yagi J, Minato N, Tanabe K (2011) A new indicator of a favorable progress in locally advanced renal cell carcinomas: γδ T-Cells in peripheral blood. Anticancer Res (in press)
17. M Hintz A Reichenberg B Altincicek U Bahr RM Gschwind AK Kollas E Beck J Wiesner M Eberl H Jomaa 2001 Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli FEBS Lett 509 317 322 11741609 10.1016/S0014-5793(01)03191-X 1:CAS:528:DC%2BD3MXovF2hs7w%3D (Pubitemid 34015963)
18. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
19. DJ Reeves CY Liu 2009 Treatment of metastatic renal cell carcinoma Cancer Chemother Pharmacol 64 11 25 19343348 10.1007/s00280-009-0983-z 1:CAS:528:DC%2BD1MXlt1Kjsb0%3D
20. MB Atkins 2009 Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy Med Oncol 26 Suppl 1 18 22 19165638 10.1007/s12032-008-9148-x
21. J Bellmunt 2009 Future developments in renal cell carcinoma Ann Oncol 20 Suppl 1 113 117
22. DR Feldman MS Baum MS Ginsberg H Hassoun CD Flombaum S Velasco P Fischer E Ronnen N Ishill S Patil RJ Motzer 2009 Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 27 1432 1439 19224847 10.1200/JCO.2008.19.0108 1:CAS:528: DC%2BD1MXksF2hs7w%3D
23. B Escudier C Szczylik TF Hutson T Demkow M Staehler F Rolland S Negrier N Laferriere UJ Scheuring D Cella S Shah RM Bukowski 2009 Randomized phase II trial of first-line treatment with sorafenib versus interferon α-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 1280 1289 19171708 10.1200/JCO.2008.19.3342 1:CAS:528:DC%2BD1MXktFKhsb8%3D
24. RJ Motzer GR Hudes BD Curti DF McDermott BJ Escudier S Negrier B Duclos L Moore T O'Toole JP Boni JP Dutcher 2007 Phase I/II trial of temsirolimus combined with interferon α for advanced renal cell carcinoma J Clin Oncol 25 3958 3964 17761980 10.1200/JCO.2006.10.5916 1:CAS:528:DC%2BD2sXhtFanu73K (Pubitemid 47477274)
25. DF McDermott 2009 The application of high-dose interleukin-2 for metastatic renal cell carcinoma Med Oncol 26 Suppl 1 13 17 19148594 10.1007/s12032-008-9152-1
26. H Kobayashi Y Tanaka J Yagi Y Osaka H Nakazawa T Uchiyama N Minato H Toma 2007 Safety profile and anti-tumor effects of adoptive immunotherapy using γδ T cells against advanced renal cell carcinoma: a pilot study Cancer Immunol Immunother 56 469 476 16850345 10.1007/s00262-006-0199-6 1:CAS:528:DC%2BD2sXht1yhsLg%3D (Pubitemid 46204533)
27. CT Morita EM Beckman JF Bukowski Y Tanaka H Band BR Bloom DE Golan MB Brenner 1995 Direct presentation of nonpeptide prenyl pyrophosphate antigens to human γδ T cells Immunity 3 495 507 7584140 10.1016/1074-7613(95) 90178-7 1:CAS:528:DyaK2MXovFymsLk%3D
28. CT Morita C Jin G Sarikonda H Wang 2007 Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens Immunol Rev 215 59 76 17291279 10.1111/j.1600-065X.2006.00479.x 1:CAS:528:DC%2BD2sXjsVKrtro%3D (Pubitemid 46212230)
29. V Kunzmann E Bauer J Feurle F Weissinger HP Tony M Wilhelm 2000 Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma Blood 96 384 394 10887096 1:CAS:528:DC%2BD3cXltVGht7c%3D
30. M Wilhelm V Kunzmann S Eckstein P Reimer F Weissinger T Ruediger HP Tony 2003 γδ T cells for immune therapy of patients with lymphoid malignancies Blood 102 200 206 1:CAS:528:DC%2BD3sXltFemurk%3D
31. F Dieli D Vermijlen F Fulfaro N Caccamo S Meraviglia G Cicero A Roberts S Buccheri M D'Asaro N Gebbia A Salerno M Eberl AC Hayday 2007 Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer Cancer Res 67 7450 7457 17671215 10.1158/0008-5472.CAN-07-0199 1:CAS:528:DC%2BD2sXosVemtLY%3D (Pubitemid 47206575)
32. V Kunzmann M Wilhelm 2005 Anti-lymphoma effect of γδ T cells Leuk Lymphoma 46 671 680 16019504 10.1080/10428190500051893 1:CAS:528: DC%2BD2MXksVejsrg%3D (Pubitemid 40775215)
33. D Santini F Martini ME Fratto S Galluzzo B Vincenzi C Agrati F Turchi P Piacentini L Rocci JS Manavalan G Tonini F Poccia 2009 In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients Cancer Immunol Immunother 58 31 38 18458903 10.1007/s00262-008- 0521-6 1:CAS:528:DC%2BD1cXht1yqs7jF
34. LS Lamb Jr 2009 γδ T cells as immune effectors against high-grade gliomas Immunol Res 45 85 95 19711198 10.1007/s12026-009-8114-9
35. U Laggner JS Lopez G Perera VS Warbey A Sita-Lumsden MJ O'Doherty A Hayday M Harries FO Nestle 2009 Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy Clin Immunol 131 367 373 19250873 10.1016/j.clim.2009.01.008 1:CAS:528: DC%2BD1MXmtVKksb4%3D
36. E Viey G Fromont B Escudier Y Morel S Da Rocha S Chouaib A Caignard 2005 Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma J Immunol 174 1338 1347 15661891 1:CAS:528:DC%2BD2MXlsFygsQ%3D%3D
37. H Sicard S Ingoure B Luciani C Serraz JJ Fournie M Bonneville J Tiollier F Romagne 2005 In vivo immunomanipulation of Vγ9 Vδ2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model J Immunol 175 5471 5480 16210655 1:CAS:528:DC%2BD2MXhtVyltr%2FO (Pubitemid 41456434)
38. HM Buckler SJ Mercer CE Davison S Hollis PC Richardson DG Anderson 1998 Evaluation of adverse experiences related to pamidronate infusion in Paget's disease of bone Ann Rheum Dis 57 572 9849319 10.1136/ard.57.9.572 1:STN:280:DyaK1M%2Fms1Wrsw%3D%3D (Pubitemid 28474067)
39. S Adami AK Bhalla R Dorizzi F Montesanti S Rosini G Salvagno V Lo Cascio 1987 The acute-phase response after bisphosphonate administration Calcif Tissue Int 41 326 331 3124942 10.1007/BF02556671 1:STN:280:DyaL1c7jsFCgtQ%3D%3D
40. OP Purohit C Anthony CR Radstone J Owen RE Coleman 1994 High-dose intravenous pamidronate for metastatic bone pain Br J Cancer 70 554 558 8080746 10.1038/bjc.1994.344 1:STN:280:DyaK2czmtF2msg%3D%3D (Pubitemid 24268564)
41. M Gnant B Mlineritsch W Schippinger G Luschin-Ebengreuth S Postlberger C Menzel R Jakesz, et al. 2009 Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 679 691 19213681 10.1056/NEJMoa0806285 1:CAS:528:DC%2BD1MXhvVyisbk%3D
42. N Bivi M Romanello R Harrison I Clarke DC Hoyle L Moro F Ortolani A Bonetti F Quadrifoglio G Tell D Delneri 2009 Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection Genome Biol 10 R93.1 R93.11 10.1186/gb-2009-10-9-r93
43. H Kobayashi Y Tanaka H Shimmura N Minato K Tanabe 2010 Complete remission of lung metastasis following adoptive immunotherapy using activated autologous γδ T-cells in a patient with renal cell carcinoma Anticancer Res 30 575 580 20332473 1:CAS:528:DC%2BC3cXksFCqsLg%3D
44. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs, IRAC Press, Lyon